

Insulin Resistance and Hypertension in the Absence of Subcutaneous Fat

Ajay Chaudhuri, MBBS, MRCP, Joseph L. Izzo, Jr, MD, FACP

State University of New York at Buffalo

When a patient presents with insulin resistance, a red flag for cardiovascular risk appears. What is the contribution of visceral fat to this syndrome? What are the risks and benefits of the treatment options for the coexistent cardiovascular risk factors?

[Rev Cardiovasc Med. 2000;1(2):120-124]

Key words: Antihypertensive therapy • Hypertension • Insulin resistance • Lipid-lowering drugs • Lipodystrophy

A 38-year-old white woman with a complex past medical history of dermatomyositis and lipodystrophy was referred for management of hypertension and hyperlipidemia.

History

Dermatomyositis was diagnosed in this patient at age 6. She was treated initially with prednisone, and the condition was considered inactive after she reached age 14. At age 21, the patient first experienced mild hypertension (blood pressure [BP], 156-166/100 mm Hg), but the workup for secondary causes was negative. BP was initially controlled with a diuretic and later with the combination of lisinopril and hydrochlorothiazide. At age 25, she underwent a total abdominal hysterectomy for high-grade cervical atypia. She described herself as being “very skinny” for as long as she could remember, and the diagnosis of generalized lipodystrophy was established when she was 28. Shortly thereafter, the discovery of hepatomegaly by CT scan prompted a liver biopsy, which revealed significant fatty infiltration.

Hyperlipidemia was first established in this patient at age 32 (total cholesterol, 302 mg/dL; low-density lipoprotein [LDL], 210 mg/dL; high-density lipoprotein [HDL], 37 mg/dL; and triglycerides, 236 mg/dL). Therapy with atorvastatin calcium, 10 mg daily, had been started 2 years earlier but was discontinued because of liver enzyme increases. Fasting glucose level was 121 mg/dL, and an oral glucose tolerance test revealed a 2-hour glucose level of 263 mg/dL.

The patient said that her liver size had begun to decrease within the last few months. A recent CT scan of the abdomen revealed a decrease in liver size and a marked reduction in the degree of fatty infiltration, compared with a CT scan performed 6 months previously. During this 6-month period, BP had decreased about

20 mm Hg to the lowest levels she had seen in years. Medications included bisoprolol/hydrochlorothiazide, 10/6.25 mg; quinapril, 40 mg; sustained-release verapamil, 240 mg; and conjugated estrogens, 0.625 mg.

The patient felt reasonably healthy and was employed as a graphic artist. She was physically active and admitted to drinking “1 to 2 beers occasionally” on weekends. She had a 20-pack-year smoking history but had quit smoking 6 years ago and denied any illicit drug use. Her family history was positive for rheumatoid arthritis and hypothyroidism in her mother, gout in her father, and hypertension in her maternal grandmother.

Physical examination

She presented as an extremely asthenic woman with no subcutaneous fat present on her face, thorax, or extremities. She weighed 53.6 kg (118 lb), and her height was 164 cm (5 ft 4 in). BP was 130/80 mm Hg in the right arm and 122/78 mm Hg in the left arm, sitting, with a heart rate of 56 beats per minute. Cardiovascular examination was entirely unremarkable, and peripheral pulses were strong and intact. Her abdomen was slightly distended, and the liver span was 14 cm, with the liver edge smooth and nontender. There was no shifting dullness on percussion or bruits on auscultation. Neurologic examination results were normal.

Laboratory data

A complete blood count revealed only mild anemia, with a hematocrit of 39%. Electrolytes were normal, and blood urea nitrogen and creatinine levels were 12 and 0.7 mg/dL, respectively. Liver function test results were mixed: albumin was 4.2 g/dL; bilirubin,

0.6 mg/dL; aspartate aminotransferase, borderline at 36 U/L; and γ -glutamyltransferase, elevated at 119 U/L. Total cholesterol was 198 mg/dL; HDL, 39 mg/dL; LDL, 86 mg/dL; triglycerides, 364 mg/dL. Creatine kinase level was elevated at 509 U/L, but the erythrocyte sedimentation rate and coagulation indices were normal. Urinalysis results were normal, but creatinine clearance was elevated at 122 mL/min. Fasting glucose level was 91 mg/dL, but C-peptide was 1.7 ng/mL (normal, 0.5 to 2 ng/mL), and insulin was 36 μ U/mL (normal, less than 20 μ U/mL).

Discussion

Insulin resistance, lipodystrophy, and central obesity. Insulin resistance, in a physiologic sense, can be defined simply as an impaired response to exogenous or endogenous insulin.¹ The pattern of obesity in the insulin resistance syndrome has been characterized as “central obesity,” with increased waist-hip ratio and increased visceral fat demonstrable on abdominal CT or magnetic resonance studies. Insulin resistance in this “very skinny” woman

with lipodystrophy and essentially no subcutaneous or peripheral adipose tissue demonstrates that the insulin resistance syndrome is largely dependent on the presence of intra-abdominal, rather than subcutaneous, fat. In this case, the fatty infiltration of the liver could be related to the insulin resistance or be a manifestation of visceral fat deposition.² The relationship between the degree of fatty infiltration and the systemic BP strongly suggests a common etiology of the 2 conditions, and the reversal of fatty infiltration could be related to an improvement in insulin resistance. The terms lipodystrophy and lipoatrophy are generally synonymous and refer to conditions in which subcutaneous fat is absent. Lipoatrophic diabetes is a recognized syndrome of unknown etiology that represents a subtype of the broader condition of diabetes mellitus.³

Numerous mechanisms for insulin resistance in visceral adiposity have been suggested, one of which is increased fatty acid liberation into the portal vein, resulting in a greater supply of fatty acids to the muscle; the fatty acids then decrease glucose oxida-

Main Points

- The insulin resistance syndrome depends largely on intra-abdominal, rather than subcutaneous, fat.
- Defects in the insulin signaling pathway may be caused by the effects of tumor necrosis factor- α (released by adipose tissue) or by activation of protein kinase C (by fatty acid moieties).
- Reduced glucose uptake in skeletal muscle may play a prominent role in insulin resistance.
- The insulin resistance syndrome includes central obesity, hypertension, dyslipidemia, elevated prothrombotic and antifibrinolytic factors, and increased risk of coronary artery disease—in the absence of diabetes.
- For controlling blood pressure in patients with insulin resistance, options include angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.


tion.⁴ It has also been shown that visceral adipocytes are larger than peripheral adipocytes and, therefore, are more prone to liberate fatty acids.⁵ Defects in the insulin signaling pathway may be due to activation of protein kinase C by fatty acid moieties or to the effects of tumor necrosis factor- α released by adipose tissue (Figure).^{4,6} Resistance is generally said to be present if the fasting insulin concentration in normoglycemic individuals is above 15 μ U/mL.^{7,8}

Insulin resistance and skeletal muscle. Another interesting aspect in this case is the history of dermatomyositis and the potential role of skeletal muscle

glucose metabolism in the genesis of insulin resistance. In healthy persons, more than two thirds of insulin-induced glucose uptake occurs in muscle, while about 10% occurs in adipose tissue.⁹ Therefore, reduced glucose uptake in skeletal muscle can have a prominent role in insulin resistance. The type of muscle fibers present may also affect glucose uptake; type 1 fibers of muscle are insulin-sensitive, while type 2b fibers tend to be insulin-resistant.¹⁰ Decreased insulin sensitivity has been reported in muscular disorders in which fiber composition is altered¹¹ but not specifically in dermatomyositis.

Antibodies and insulin resistance. Antibodies to insulin or insulin receptors have been reported in association with autoimmune illnesses. Such patients usually demonstrate severe insulin resistance, elevated fasting glucose levels, and acanthosis nigricans,³ none of which occurred in the present case.

Figure. Insulin signaling pathway defects. α , α subunit; β , β subunit; TNF- α , tumor necrosis factor- α ; T, tyrosine; S, serine; P, phosphorylation; PI3-kinase, phosphatidylinositol-3 kinase; RaS, rat sarcoma protein; solid arrow, stimulation; broken arrow, inhibition.²²



The insulin resistance syndrome and associated disorders. The recognition of the clustering of several other cardiovascular risk factors with insulin resistance has expanded the meaning of the original physiologic term to include a complex syndrome of central obesity, hypertension, dyslipidemia (high triglycerides, low HDL, increased small-dense LDL), elevated prothrombotic and antifibrinolytic factors, and increased risk of coronary artery disease.¹² This constellation of risk factors in the absence of diabetes is now known by various names, including the insulin resistance syndrome, the metabolic syndrome X, and the cardiovascular dysmetabolic syndrome. Insulin resistance should be suspected if any of the conditions associated with it (see Table) are present.

More recently, it has been appreciated that other conditions are associated with insulin resistance. HIV is also associated with generalized lipodystrophy.¹³ Homology between the genetic sequence of 2 proteins responsible for peripheral adipocyte differentiation and cleavage of triglycerides and the HIV protease has been suggested as a possible mechanism.¹³

Hypertension and insulin resistance. The precise relationship between insulin resistance and hypertension remains unclear. The insulin resistance syndrome is associated with increased sympathetic activity and increased renal salt retention.¹⁴ There is some evidence that a primary increase in sympathetic activity can cause parallel increases in forearm insulin resistance and BP. Catecholamines cause insulin resistance directly, as is observed in patients with pheochromocytoma.¹⁵ On the other hand, there is also evidence that insulin can stimulate the sympathetic nervous system.¹⁶ Whatever the

Table
Causes of Insulin Resistance

Common	Uncommon
Type 2 diabetes mellitus	Type A syndrome
Obesity associated with central adiposity	(insulin receptor defects)
Gestational diabetes mellitus	Type B syndrome
Impaired fasting glucose (> 110 mg/dL)	(antibody-related)
Strong family history of type 2 diabetes mellitus	Lipoatrophy
Hypertension	(congenital/acquired)
Polycystic ovarian syndrome	Leprechaunism
AIDS-related lipodystrophy	Cushing syndrome
Pregnancy	Acromegaly
Hyperthyroidism	Pheochromocytoma
Cirrhosis	Rabson-Mendenhall syndrome
Acute illness and surgery	Rare genetic syndromes
	Renal failure

pathogenesis of the syndrome, chronic hypertension is not caused by insulin alone, at least in humans. Insulin is a powerful vasodilator that acts through endothelial mechanisms to stimulate the synthesis of nitric oxide (NO) and cyclic guanosine monophosphate (GMP).^{17,18} A deficiency in the NO-cyclic GMP axis, however, could diminish the vasodilating effects of insulin and contribute to increased vascular resistance.

Treatment of insulin resistance. Treatment options in insulin resistance begin with exercise and diet. Pharmacotherapy with insulin sensitizers may help reduce central adiposity and hyperinsulinemia. In the present case, metformin therapy could be considered, although it has not been shown to reduce BP consistently.

Thiazolidinediones, which are attractive therapeutic possibilities for most insulin-resistant people, would probably not be appropriate in this patient because of the presence of liver

function abnormalities and the potential for liver toxicity.

For BP control in diabetes or insulin resistance, angiotensin-converting enzyme (ACE) inhibitors are clearly preferred¹⁹ and should be continued as the cornerstone of hypertension management in this case. Angiotensin receptor blockers appear to be favorable alternatives for those intolerant of ACE inhibitors. Thiazides and β -blockers have also demonstrated long-term benefit in cardiovascular mortality and morbidity and are also useful for treating patients with diabetes.²⁰ Calcium antagonists do not appear to confer the same degree of cardioprotection as ACE inhibitors in patients with diabetes.²¹

Concomitant management of dyslipidemia in patients with insulin resistance is often overlooked and may be equally important as effective hypertension management. In such patients, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase in-

inhibitors are useful to decrease LDL levels, and fibric acid derivatives are sometimes used for management of hypertriglyceridemia. Niacin should be avoided generally, because it can worsen glucose tolerance in patients with insulin resistance.

References

- American Diabetes Association. Consensus Development Conference on Insulin Resistance. *Diabetes Care*. 1998;21:310-314.
- Knobler H, Schattner A, Zhornicki T, et al. Fatty liver—an additional and treatable feature of the insulin resistance syndrome. *QJM*. 1999;92:73-79.
- Goldstein BJ. Syndromes of extreme insulin resistance. In: Kahn CR, Weir GC, eds. *Joslin's Diabetes Mellitus*. 13th ed. Malvern, Pa: Lea and Febiger; 1994:282-299.
- Chisolm DJ, Campbell LV, Kraegen EW. Pathogenesis of the insulin resistance syndrome (syndrome X). *Clin Exper Pharmacol Physiol*. 1997;24:782-784.
- Kissebah AH, Videlund N, Murray R, et al. Relation of body fat distribution to metabolic complications of obesity. *J Clin Endocrinol Metab*. 1982;54:254-260.
- Hotamisligil US, Peraldi P, Budavari A, et al. IRS-1 mediated inhibition of insulin receptor tyrosine kinase activity in TNF- α and obesity induced insulin resistance. *Science*. 1996;271:665-667.
- Laakso M. How good a marker is insulin level for insulin resistance? *Am J Epidemiol*. 1993;137:959-965.
- Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. *N Engl J Med*. 1996;334:952-957.
- Weir GC, Leahy JL. Pathogenesis of non-insulin-dependent (type 2) diabetes mellitus. In: Kahn CR, Weir GC, eds. *Joslin's Diabetes Mellitus*. 13th ed. Malvern, Pa: Lea and Febiger; 1994:240-264.
- Chipkin SR, Kelly KL, Ruderman NB. Hormone-fuel interrelationships: fed state, starvation, and diabetes mellitus. In: Kahn CR, Weir GC, eds. *Joslin's Diabetes Mellitus*. 13th ed. Malvern, Pa: Lea and Febiger; 1994:97-115.
- Vestergaard H, Klein HH, Hansen T, et al. Severe insulin resistant diabetes mellitus in patients with congenital muscle fiber type disproportion myopathy. *J Clin Invest*. 1995;95:1925-1932.
- Reaven GM. Role of insulin resistance in human disease. *Diabetes*. 1988;37:1595-1607.
- Qaqish RB, Fisher E, Rublein J, Wohl DA. HIV-associated lipodystrophy syndrome. *Pharmacotherapy*. 2000;20:13-22.
- Julius S, Gudbrandsson T, Jamerson K, Andersson O. The interconnection between sympathetics, microcirculation, and insulin resistance in hypertension. *Blood Pressure*. 1992;1:9-19.
- Izzo JL, Jr, Swislocki ALM. Symposium on insulin and cardiovascular disease. Workshop III - Insulin resistance: Is it truly the link? *Am J Med*. 1991;90(suppl 2A):26S-31S.
- Reaven GM, Lithell H, Lindsberg L. Hypertension and associated metabolic abnormalities—the role of insulin resistance and the sympathoadrenal system. *N Engl J Med*. 1996;334:374-381.
- Steinberg HO, Brechtel G, Johnson A, et al. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. *J Clin Invest*. 1994;94:1172-1179.
- Grover A, Padginton C, Wilson MF, et al. Insulin attenuates norepinephrine-induced venoconstriction: an ultrasonographic study. *Hypertens*. 1995;25:779-784.
- Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). *Arch Intern Med*. 1997;157:2413-2446.
- UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). *BMJ*. 1998;317:713-720.
- Estacio RO, Jeffery RW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. *N Engl J Med*. 1998;338:645-652.
- Hunter SJ, Garvey WT. Insulin action and insulin resistance: diseases involving defects in insulin receptors, signal transduction, and the glucose transport effector system. *Am J Med*. 1998;105:331-345.

MULTI-LINK SYSTEM™ Cannula System

CAUTION: Read and understand this device to use by or in the order of a physician. The relevant instructions for use, contraindications, warnings, precautions and potential adverse events are included as follows (refer to instructions for use for complete information).

INDICATIONS

The MULTI-LINK SYSTEM™ Cannula System is indicated for improving coronary blood flow in the following (also contraindications of treatment):

- Patients with symptomatic ischemic heart disease due to coronary artery disease with stenosis ranging from 3.0 to 4.0 mm.
- Treatment of abrupt or threatened closure of patients with failed interventional therapy of lesions < 35 mm in length with reference vessel diameter of 3.5 to 4.0 mm.
- Long term outcome for this permanent implant is unknown at present.

CONTRAINDICATIONS

The MULTI-LINK SYSTEM™ Cannula System is contraindicated to use in:

- Patients in whom anti-clotting and/or anti-coagulant therapy is contraindicated.
- Patients judged to have a lesion that prevents complete inflation of an angioplasty balloon.

WARNINGS AND PRECAUTIONS (see also contraindications of treatment)

- Judicious selection of patients is necessary since the use of this device carries the associated risk of vascular thrombosis, vascular complications and/or device-related events.
- Patients subject to TIA, stroke, stroke risk or other vascular disease may be at increased risk of stroke or other vascular events.
- Implantation of the stent should be performed only by physicians who have received appropriate training.
- Stent placement should only be performed at hospitals where emergency coronary artery bypass graft surgery can be readily performed.
- Subsequent restenosis may require repeat dilation of the artery segment containing the stent. The long-term outcome following repeat dilation of restenosed stents is unknown at present.
- When multiple stents are required, stent materials should be of similar composition.

Stent Handling—Precautions

- For single use only. Do not sterilize or reuse. Highly product "Use By" date.
- Do not remove stent from its delivery catheter as removal may damage the stent and/or lead to stent dislodgement. Stent system is intended to be used as a system.
- Delivery system should not be used in conjunction with other stents.
- Special care must be taken not to handle or in any way change the stent on the catheter. This is most important during stent system removal from packaging. placement new guide wire, and advancement through rotating hemostatic valve adapter and guiding catheter hub.
- Do not "yank" the loaded stent with your fingers as this action may loosen the stent from the delivery catheter.
- Use only the appropriate delivery initiation media. Do not use air or any gaseous medium to inflate the balloon as this may cause vessel rupture and difficulty in dissection of the stent.

Stent Placement—Precautions

- Do not prepare or use delivery catheter prior to stent placement other than as described. Use balloon pumping technique described in section 4.3.2 Delivery System Preparation.
- The working length of the catheter has changed from 137 cm to 143 cm. The proximal portion, from the handle and manual markers to the inflation port, is longer than previous catheters.
- The loaded stent diameter refers to expanded stent inner diameter. Previous coronary stent systems referred to outside diameter of the expanded stent.
- Implanting a stent may lead to dissection of the vessel distal and/or proximal to the stent and may cause acute closure of the vessel requiring additional intervention (ACU). Further dilation, placement of additional stents, or other.

- When loading/multiple lesions, the distal rotor direction is initiated, followed by starting of the proximal rotor. Starting in this order provides the need to cross the proximal stent in placement of the distal stent and reduces the chances for dislodging the proximal stent.
- Do not expand the stent if it is not properly positioned in the vessel. (See Stent/System Removal—Precautions.)
- Placement of a stent has the potential to compromise side branch perfusion.
- Do not exceed Rated Burst Pressure as indicated on product label. Balloon pressure should be monitored during inflation. Use of pressure higher than specified on product label may result in a ruptured balloon with possible vessel damage and dissection.
- An unexpanded stent may be trapped into the guiding catheter over time only. Subsequent movement in and out through the distal end of the guiding catheter should not be performed, as the stent may be damaged when retracting the angiographic stent back into the guiding catheter. Should any resistance be felt at any time during withdrawal of the Coronary Stent System, the wire/catheter assembly (removed) as a single unit.
- Stent delivery methods (use of additional wires, wires under backup) may result in additional trauma to the coronary vasculature and/or the residual acute site. Complications may include bleeding, thrombosis or perforation.

Stent/System Removal—Precautions

- Should any resistance be felt at any time during wire lesion access or removal of the Delivery System post-stent implantation, the entire system should be removed as a single unit.
- When removing the Delivery System as a single unit:
- Do not retract the Delivery System into the guiding catheter.
- Position the proximal balloon marker just distal to the tip of the guiding catheter.
- Advance the guide wire into the coronary anatomy as far distally as safely possible.
- Engage the rotating hemostatic valve to secure the Delivery System to the guiding catheter; then remove the guiding catheter, guide wire and Delivery System as a single unit.

Failure to follow these steps and/or applying excessive force to the Delivery System, can potentially result in loss or damage to the stent and/or Delivery System components.

If it is necessary to retain guide wire position for subsequent intervention, insert the guide wire in place and remove all other system components.

Post-Implant—Precautions

- Care must be maintained during a newly deployed stent with a coronary guide wire or catheter catheter to avoid disrupting the stent position.
 - Do not perform magnetic resonance imaging (MRI) on patients post-stent implantation until the stent has completely endothelialized (eight weeks) to minimize the potential for migration. The stent may cause a 10-fold or more increase in the duration of the magnetic field.
- POTENTIAL ADVERSE EFFECTS:**
- Adverse events (in alphabetical order) may be associated with the use of a coronary stent in native coronary arteries including those listed in Table 2:
- Acute myocardial infarction
 - Angioplasty, including IV and PT
 - Death
 - Dissection
 - Drug reactions to anti-clotting agent/contrast medium
 - Distal embolism (air, tissue or thrombotic emboli)
 - Emergent Coronary Artery Bypass Surgery
 - Hemorrhage, including intracranial
 - Hypotension/hypertension
 - Infection and perforation: perforation site
 - Ischemia, myocardial
 - Perforation
 - Pseudoaneurysm, localized
 - Restenosis of treated segment
 - Spasm
 - Stent embolization
 - Stent thrombosis/occlusion
 - Stent thrombosis/vascular accident
 - Total occlusion of the coronary artery

©2000 Guidant Corporation. All rights reserved.